Designer Drugs Update 2019: Phenibut, Synthetic Opioids, & More (1.5 CME)
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that/about:
1.) Identify emerging designer drugs, including phenibut, synthetic opioids, and others.
2.) Recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use.
3.) Discuss treatment of medical and psychiatric complications resulting from use of designer drugs.
|Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects. Session description: This focus session will inform attendees with a discussion�"including clinical case examples�"that will focus on emerging designer drugs, including phenibut, synthetic opioids, and others. Use of these drugs has caused significant medical and psychiatric consequences, including multiple deaths, which has received recent media attention. The presentation will be evidence-based and draw from existing medical literature, and will also include the panelists’ clinical experience with patients experiencing designer drug use and complications. The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications. Attention will be given to specific populations that have been shown to be using these designer drugs. The presenters are experienced clinicians who have been involved in evaluation of patients using designer drugs. The presenters have also published about designer drugs in peer-reviewed journals. Attendees will be able to share their own experiences with patient use of designer drugs to enrich the discussion. Time will be allowed for questions to the panelists so that there will be significant interaction during this focus session. Conclusions: This focus session will provide attendees with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications.|
Michael F. Weaver
Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine. He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.